VCP Scanner
Stock Screener
Filter stocks with fundamental & technical criteria
Market Themes
Curated industry baskets & thematic leaders
Earnings Hub
Calendar, EPS surprise stats & earnings transcripts
Market News
Real-time market intelligence & AI overviews
Insider Buying
SEC Form 4 corporate insider purchases
LearnAll lessons
Candlestick Patterns44 candles, each on two real charts
Pattern GuidesThe playbooks' setups on real breakouts
GlossaryInvesting terms in plain English
MinerviniVCP SetupsTrend Template
O'NeilCup with HandleFlat BaseDouble BottomCANSLIM Leaders
QullamaggieHigh Tight FlagsFlag BreakoutsEpisodic PivotsMomentum Leaders
KellWedge PopEMA Crossback
LivermorePivotal Points
PatternsFalling Wedge & ChannelBase Breakouts
View All Playbooks...
BreakoutsScanner
FAANG & Tech
AAPL vs MSFTNVDA vs AMDGOOGL vs META
Cloud & Cyber
CRM vs NOWCRWD vs PANWSNOW vs DDOG
Consumer & Auto
TSLA vs FAMZN vs WMTNFLX vs DIS
Finance & Crypto
JPM vs BACV vs MACOIN vs MSTR
Index & ETFs
SPY vs QQQVTI vs VOOSPY vs IWM
Compare Any Stocks...
DCF ValuationCalculate intrinsic value of US stocks
Market ValuationBuffett indicator, CAPE & macro gauges
Total ReturnSee dividends + price return history
DCA CalculatorSimulate recurring buys & compounding
VisualizeInteractive multi-year financial charts
Watchlist
BreakoutsScanner
WatchlistPricing
Ctrl K
Pricing
COLL
← Back to Screener
VCP ScannerFree US Stock Screener & Financial Analysis

Find stocks. Analyze deeply. Research with clarity.

Data updated daily

Product

  • Screener
  • Scanner
  • Themes
  • Valuation
  • Total Return
  • DCA Calculator
  • Pricing
  • News
  • Earnings

Resources

  • Market Valuation
  • Compare
  • Insider Activity
  • Methodology
  • How It Works
  • Glossary
  • Learn

Get Ideas

Get weekly market insights — free

© 2026 VCP Scanner
AboutPrivacyTermsRefund Policy
Not financial advice. Do your own research.
ScreenerBreakoutsScannerWatchlist
COLLCollegium Pharmaceutical, Inc.
$25.93$841M
Overview & Tools
OverviewChart Terminal ↗Visualize
Valuation & Forecasts
Valuation ModelsEstimatesDCF Model
Price & Analyst Data
Analyst TargetsPrice History
Financial Statements
Income StatementBalance SheetCash FlowRatios & Margins
Performance
P/E HistoryRevenue HistoryEarnings HistoryDividend HistoryTotal Return
Discovery & Screens
Live BreakoutsStock ScreenerOwnership
COLL logo

Collegium Pharmaceutical, Inc.

COLL
NASDAQ · Specialty & Generic Drugs
$25.93
At close - Nov 18, 4:00 PM EST - USD
Market Cap$841M
P/E26.6x
52W High$50.79
Volume493.64K
OverviewTerminalAnalysisFinancialsValuationEarningsBreakoutsOwnership
VCP Research Verdict2026Q3

Leverage-Heavy Specialty Pharma Converts Cash Despite Earnings Volatility

Collegium's revenue growth has decelerated sharply, from 31.4% year over year in 2025Q3 to 3.3% in 2026Q3, suggesting its earlier expansion is maturing.

GrowthMixed
ProfitabilityModerate
ValuationAttractive
TechnicalsWeak
Explore valuation models
MARKET ACTION

COLL price & volume

Price trend, volume and key moving averages

Launch Terminal
Loading chart...
Decision Checklist4 Core Signals

What matters now

The signals most likely to change the investment case.

01

Earnings momentum

10/12 Beats

EPS beat 10 of last 12 quarters

02

Valuation risk

+110% Peers

P/E is 110% above peer median

03

Market leadership

RS 33 · Lag

Laggard (Underperforming 67% of market)

04

Weak Trend

Below 200DMA

Price < 200DMA

Next CatalystEstimated earnings · Feb 5

Market performance

Price History →

Trailing total returns as of 11/19/2026, which may include dividends or other distributions. Benchmark is S&P 500 (^GSPC).

YTD Return
COLL-43.05%
S&P 500 (^GSPC)+6.88%
1-Year Return
COLL-42.81%
S&P 500 (^GSPC)+10.62%
3-Year Return
COLL+1.33%
S&P 500 (^GSPC)+60.28%
5-Year Return
COLL+36.12%
S&P 500 (^GSPC)+61.76%
02

Test the fundamentals

Check whether operating performance supports the current valuation.

VALUATION & INTRINSIC VALUE

Valuation Scenarios

Valuation Analysis
Trailing P/E5Y High
26.6x
Forward P/EExpansion
3.5x
EV/EBITDA0th %ile
5.1x
FCF YieldCash Flow
40.0%

Valuation vs 5-Year History

Multiple Range
Metric
Current
5Y Median
Historical Range
Percentile
P/E
26.6x
23.9x
75th· Fair
EV/EBITDA
5.1x
6.1x
0th· Low
Price/FCF
2.5x
5.7x
0th· Low
Current Multiple
5Y Median (50th %ile)

Intrinsic Value Scenarios

DCF Projection
Bear$166.62+542.6%
Base (Fair)$251.69+611.2%
Bull$446.45+1621.8%
$166.62 Bear$251.69 Base$446.45 Bull
Current Market Price: $25.93
Trades at a 89.7% discount to Base DCF ($251.69)
Open DCF & Valuation Models →Chart Terminal ↗

Growth & profitability

Annual revenue & EPS trend
Revenue FY25
$781M+23.6% YoY
Net income FY25
$63M-9.1% YoY
Free cash flow FY25
$328M+61.1% YoY
Operating margin FY25
24%-2.9 pts YoY
ROIC (FY25)14%
Avg ROIC 5Y11.5%
ROE (TTM)12.5%
Piotroski Score6 / 9
Financial Statements →
03

Monitor what changed

Recent results and news deserve attention only when they alter the forward view.

OPERATING RESULTS

Recent Earnings

Earnings History
EPS Beat Rate10/12 (83%)
Revenue Beat Rate8/12 (67%)
QuarterEPS (Act vs Est)Revenue (Act vs Est)
Q4 2026Latest
Nov 5, 2026
$1.96+5.4%
vs $1.86
$216M+0.1%
vs $216M
Q3 2026
Aug 6, 2026
$1.92+11.6%
vs $1.72
$200M+0.1%
vs $200M
Q2 2026
May 7, 2026
$1.76+15.8%
vs $1.52
$194M+4.9%
vs $184M
Q1 2026
Feb 26, 2026
$2.04-4.7%
vs $2.14
$205M-0.4%
vs $206M
Historical baseline: 12 quarters analyzedGAAP / Adjusted
MARKET COVERAGE

Latest News

4 Stories
Zacks Investment Research·Nov 10, 2026
Wall Street Analysts Believe Collegium Pharmaceutical (COLL) Could Rally 81.63%: Here's is How to Trade

The mean of analysts' price targets for Collegium Pharmaceutical (COLL) points to an 81.6% upside in the stock. While this highly sought-after metric has not proven reasonably effective, strong agreement among analysts in raising earnings estimates does indicate an upside in the stock.

Seeking Alpha·Nov 7, 2026
Collegium Pharmaceutical, Inc. (COLL) Q3 2026 Earnings Call Transcript

Collegium Pharmaceutical, Inc. ( COLL ) Q3 2026 Earnings Call November 5, 2026 8:00 AM EST Company Participants Ian Karp - Head of Investor Relations Vikram Karnani - CEO, President & Director Colleen Tupper - Executive VP & CFO Conference Call Participants Leszek Sulewski - Oppenheimer & Co. Inc., Research Division Daniel Christopher Clark - Leerink Partners LLC, Research Division Brandon Folkes - H.C. Wainwright & Co, LLC, Research Division Serge Belanger - Needham & Company, LLC, Research Division Alexander Xenakis - Truist Securities, Inc., Research Division Alexandra von Riesemann - Piper Sandler & Co., Research Division Presentation Operator Greetings, and welcome to the Collegium Pharmaceutical Third Quarter 2026 Earnings Conference Call.

Zacks Investment Research·Nov 5, 2026
Collegium Pharmaceutical (COLL) Tops Q3 Earnings and Revenue Estimates

Collegium Pharmaceutical (COLL) came out with quarterly earnings of $1.96 per share, beating the Zacks Consensus Estimate of $1.77 per share. This compares to earnings of $2.25 per share a year ago.

Zacks Investment Research·Nov 5, 2026
Compared to Estimates, Collegium Pharmaceutical (COLL) Q3 Earnings: A Look at Key Metrics

The headline numbers for Collegium Pharmaceutical (COLL) give insight into how the company performed in the quarter ended September 2026, but it may be worthwhile to compare some of its key metrics to Wall Street estimates and the year-ago actuals.

Filtered for Collegium Pharmaceutical, Inc.More Headlines
04

Compare before deciding

Benchmark COLL against direct peers instead of judging its metrics in isolation.

Peers Comparison

Key metrics vs top competitors for Collegium Pharmaceutical, Inc. (COLL)

Full Screener →
CompanyPriceMarket CapP/E RatioRev Growth (1Y)Net MarginROEDiv Yield
COLL logoCOLLCollegium Pharmaceutical, Inc.Current
$25.93$841.01M26.5723.62%4.68%12.49%—
HRMY logoHRMYHarmony Biosciences Holdings, Inc.
$33.11$1.92B11.0621.51%18.05%18.55%—
SUPN logoSUPNSupernus Pharmaceuticals, Inc.
$28.96$3.53B7.854.29%32.75%——
PCRX logoPCRXPacira BioSciences, Inc.
$36.48$1.43B39.483.63%5.08%5.53%—
PRGO logoPRGOPerrigo Company plc
$16.94$2.34B-1.33-2.75%-43.27%-68.13%6.79%
MCK logoMCKMcKesson Corporation
$1084.43$126.55B26.9312.36%1.12%—0.28%

Compare COLL vs Peers

Collegium Pharmaceutical, Inc. (COLL) vs competitors — business, growth, and fundamentals comparison against the closest industry rivals.

Closest Rival

vs HRMY

Most directly comparable listed peer for COLL.

Scale Benchmark

vs MCK

Larger-name benchmark to compare COLL against a more recognizable public peer.

Peer Set

Compare Top 5

vs HRMY, SUPN, PCRX, PRGO

05

Keep researching

Verify the primary filings, follow material updates, and answer the remaining questions.

COLL SEC Filings & Documents

Collegium Pharmaceutical, Inc. (COLL) SEC filings — annual & quarterly reports (10-K, 10-Q)

8-K Announcements

6
Material company update

Nov 5, 2026·SEC

Material company update

Oct 19, 2026·SEC

Material company update

Aug 13, 2026·SEC

10-K Annual Reports

3
FY 2026

Feb 26, 2026·SEC

FY 2025

Feb 27, 2025·SEC

FY 2024

Feb 22, 2024·SEC

10-Q Quarterly Reports

6
FY 2026

Nov 5, 2026·SEC

FY 2026

Aug 6, 2026·SEC

FY 2026

May 7, 2026·SEC

Get notified when COLL posts new earnings or crosses analyst targets

Free. No account needed. Unsubscribe any time.

Free. Unsubscribe any time.

COLL Frequently Asked Questions

Collegium Pharmaceutical, Inc. (COLL) stock FAQ — growth, dividends, profitability & financials explained

Growth & Financials
What is Collegium Pharmaceutical, Inc.'s revenue?

Collegium Pharmaceutical, Inc. (COLL) reported $815.2M in revenue over the trailing twelve months. Revenue was $780.6M in fiscal year 2025.

How fast is Collegium Pharmaceutical, Inc. growing?

Collegium Pharmaceutical, Inc. (COLL) grew revenue by 7.7% over the trailing twelve months, compared with the twelve months before.

Is COLL profitable?

Yes. Collegium Pharmaceutical, Inc. (COLL) earned $38.2M in net income over the trailing twelve months (a 4.7% net margin).

Dividend & Returns
What is COLL's return on equity?

Collegium Pharmaceutical, Inc. (COLL) had a return on equity (ROE) of 12.5% over the trailing twelve months. That is in line with the market's typical 10-15%.

What is Collegium Pharmaceutical, Inc.'s free cash flow?

Collegium Pharmaceutical, Inc. (COLL) generated $336.3M in free cash flow over the trailing twelve months.

What if you invested $1,000 in COLL back in 2013?

Total return calculator · dividends reinvested · 13+ years of data

See returns →